Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) Shares Outstanding (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Shares Outstanding for 12 consecutive years, with $165.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Outstanding rose 111.0% year-over-year to $165.1 million, compared with a TTM value of $165.1 million through Sep 2025, up 111.0%, and an annual FY2024 reading of $80.1 million, up 19.0% over the prior year.
  • Shares Outstanding was $165.1 million for Q3 2025 at CytomX Therapeutics, roughly flat from $164.9 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $165.1 million in Q3 2025 and bottomed at $65.0 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $79.3 million, with a median of $66.8 million recorded in 2023.
  • The sharpest move saw Shares Outstanding grew 0.61% in 2022, then soared 111.11% in 2025.
  • Year by year, Shares Outstanding stood at $65.4 million in 2021, then increased by 1.28% to $66.2 million in 2022, then grew by 1.63% to $67.3 million in 2023, then grew by 19.0% to $80.1 million in 2024, then skyrocketed by 106.08% to $165.1 million in 2025.
  • Business Quant data shows Shares Outstanding for CTMX at $165.1 million in Q3 2025, $164.9 million in Q2 2025, and $80.6 million in Q1 2025.